1. Asaf Danziger: Chief Executive Officer and Director
Mr. Danziger has been the CEO of Novocure Limited since [date]. He previously worked as the company’s CFO and as a member of its Board of Directors. Prior to joining Novocure, Mr. Danziger worked as a Vice President at IDB Group, where he focused on venture capital investment.
2. Allyson Ocean: Director
[Information not provided]
3. Kristin Stafford: Director
[Information not provided]
4. Ashley Cordova: Chief Financial Officer (Principal Financial and Accounting Officer)
[Information not provided]
5. David T. Hung: Director
[Information not provided]
6. William F. Doyle: Executive Chairman and Director
Since [date], Mr. Doyle has served as the CEO of PotashCorp, a fertilizer company. He has been a member of Novocure’s Board of Directors since 2007 and was appointed as its Chairman in [date].
7. Jeryl L. Hilleman: Director
[Information not provided]
8. Timothy J. Scannell: Director
[Information not provided]
9. William A. Vernon: Director
[Information not provided]
10. Kinyip Gabriel Leung: Director
Dr. Leung is a professor at the University of Hong Kong, where he serves as the Dean of the Li Ka Shing Faculty of Medicine. He has been a member of Novocure’s Board of Directors since 2020 and serves as the Chairman of the Board’s Audit Committee.
11. Martin J. Madden: Director
[Information not provided],
Novocure Limited currently has 1605 employees.
News about Novocure Limited Key Personnel |
Novocure, a leading global oncology company, has recently named Dr. Nicolas Leupin as their new Chief Medical Officer (CMO). Dr. Leupin s appointment comes at a crucial time for the company as it seeks to navigate both medical and financial challenges. With a strong background in the biotechnology and pharmaceutical industries, as well as extensive experience as a medical oncologist and educator, Dr. Leupin is well-positioned to steer Novocure towards success.
In his role as CMO, Dr. Leupin will be responsible for overseeing medical affairs, medical safety, and clinical development operations. This will be vital as Novocure aims to advance its clinical programs and bring innovative oncology treatmen...
|
